Published in Transl Oncol on June 01, 2012
AMPK: a contextual oncogene or tumor suppressor? Cancer Res (2013) 1.82
Dysregulated metabolism contributes to oncogenesis. Semin Cancer Biol (2015) 1.03
Metformin limits the adipocyte tumor-promoting effect on ovarian cancer. Oncotarget (2014) 0.93
Oral cancer cells may rewire alternative metabolic pathways to survive from siRNA silencing of metabolic enzymes. BMC Cancer (2014) 0.86
Is 5´-AMP-Activated Protein Kinase Both Jekyll and Hyde in Bladder Cancer? Int Neurourol J (2015) 0.85
AMPK as a potential anticancer target - friend or foe? Curr Pharm Des (2014) 0.82
Therapeutic implications of targeting energy metabolism in breast cancer. PPAR Res (2013) 0.80
ASIC1a mediates the drug resistance of human hepatocellular carcinoma via the Ca(2+)/PI3-kinase/AKT signaling pathway. Lab Invest (2016) 0.76
Need glucose to sprout: local metabolic control of angiogenesis. EMBO Mol Med (2013) 0.75
A role for PFKFB3/iPFK2 in metformin suppression of adipocyte inflammatory responses. J Mol Endocrinol (2017) 0.75
Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer (2011) 9.68
Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev (2009) 6.46
AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev (2011) 5.26
A microenvironmental model of carcinogenesis. Nat Rev Cancer (2008) 4.40
Metformin in breast cancer: time for action. J Clin Oncol (2009) 3.81
Causes and consequences of increased glucose metabolism of cancers. J Nucl Med (2008) 3.79
Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia. Curr Biol (2000) 3.28
Metformin: taking away the candy for cancer? Eur J Cancer (2010) 2.68
Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov (2011) 2.45
AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol (2010) 2.11
Activation of AMP-activated protein kinase induces p53-dependent apoptotic cell death in response to energetic stress. J Biol Chem (2007) 2.03
Cellular adaptations to hypoxia and acidosis during somatic evolution of breast cancer. Br J Cancer (2007) 2.00
Q&A: Cancer: clues from cell metabolism. Nature (2010) 1.98
Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer. Exp Mol Pathol (2009) 1.92
Adaptive landscapes and emergent phenotypes: why do cancers have high glycolysis? J Bioenerg Biomembr (2007) 1.83
AMP-activated protein kinase and cancer. Acta Physiol (Oxf) (2009) 1.64
Tumor acidity, chemoresistance and proton pump inhibitors. Future Oncol (2005) 1.57
pH and drug resistance. II. Turnover of acidic vesicles and resistance to weakly basic chemotherapeutic drugs. Biochem Pharmacol (1999) 1.48
6-Phosphofructo-2-kinase (pfkfb3) gene promoter contains hypoxia-inducible factor-1 binding sites necessary for transactivation in response to hypoxia. J Biol Chem (2004) 1.46
Hypoxia, glucose metabolism and the Warburg's effect. J Bioenerg Biomembr (2007) 1.37
Phosphorylation of the 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase/PFKFB3 family of glycolytic regulators in human cancer. Clin Cancer Res (2005) 1.26
Chemoprevention meets glucose control. Cancer Prev Res (Phila) (2010) 1.24
Metformin and neoplasia: implications and indications. Pharmacol Ther (2011) 1.20
Enhancing AMPK activation during ischemia protects the diabetic heart against reperfusion injury. Am J Physiol Heart Circ Physiol (2011) 1.17
A small molecule AMPK activator protects the heart against ischemia-reperfusion injury. J Mol Cell Cardiol (2011) 1.15
Glucose deprivation-induced metabolic oxidative stress and cancer therapy. J Cancer Res Ther (2009) 1.13
Acute metabolic alkalosis enhances response of C3H mouse mammary tumors to the weak base mitoxantrone. Neoplasia (2001) 1.13
Regulation of mTORC1 signaling by pH. PLoS One (2011) 1.04
Autophagy: regulation by energy sensing. Curr Biol (2011) 1.00
Structure-based development of small molecule PFKFB3 inhibitors: a framework for potential cancer therapeutic agents targeting the Warburg effect. PLoS One (2011) 0.96
Modeling core metabolism in cancer cells: surveying the topology underlying the Warburg effect. PLoS One (2010) 0.95
Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73. BMC Cancer (2010) 0.84
Absence of Crabtree effect in human melanoma cells adapted to growth at low pH: reversal by respiratory inhibitors. Cancer Res (2001) 0.81
Acidosis plus melphalan induces nitric oxide-mediated tumor regression in an isolated limb perfusion human melanoma xenograft model. Surgery (2002) 0.79
A systematic review of low back pain cost of illness studies in the United States and internationally. Spine J (2007) 6.01
Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis. Value Health (2007) 3.93
Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. Circulation (2005) 2.85
Autophagy in cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and NFκB activation in the tumor stromal microenvironment. Cell Cycle (2010) 2.80
Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res (2003) 2.24
The autophagic tumor stroma model of cancer or "battery-operated tumor growth": A simple solution to the autophagy paradox. Cell Cycle (2010) 2.10
HIF1-alpha functions as a tumor promoter in cancer associated fibroblasts, and as a tumor suppressor in breast cancer cells: Autophagy drives compartment-specific oncogenesis. Cell Cycle (2010) 1.89
Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol Cell Biol (2006) 1.89
Clinical management of salivary gland hypofunction and xerostomia in head-and-neck cancer patients: successes and barriers. Int J Radiat Oncol Biol Phys (2010) 1.84
Carboxyl-terminal transactivation activity of hypoxia-inducible factor 1 alpha is governed by a von Hippel-Lindau protein-independent, hydroxylation-regulated association with p300/CBP. Mol Cell Biol (2002) 1.67
MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300. J Biol Chem (2003) 1.66
Prevention of pertussis: recommendations derived from the second Global Pertussis Initiative roundtable meeting. Vaccine (2006) 1.65
Suppression of apoptosis in the protein kinase Cdelta null mouse in vivo. J Biol Chem (2006) 1.61
Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. J Am Coll Cardiol (2005) 1.61
Regulation of intracellular pH in human melanoma: potential therapeutic implications. Mol Cancer Ther (2002) 1.57
VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma. Int J Radiat Oncol Biol Phys (2007) 1.55
Hypoxia-inducible factor-1-mediated expression of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) gene. Its possible role in the Warburg effect. J Biol Chem (2001) 1.55
Interaction between HIF-1 alpha (ODD) and hARD1 does not induce acetylation and destabilization of HIF-1 alpha. FEBS Lett (2005) 1.51
Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM). J Thromb Thrombolysis (2007) 1.47
6-Phosphofructo-2-kinase (pfkfb3) gene promoter contains hypoxia-inducible factor-1 binding sites necessary for transactivation in response to hypoxia. J Biol Chem (2004) 1.46
Hypoxia, glucose metabolism and the Warburg's effect. J Bioenerg Biomembr (2007) 1.37
Radiation-induced salivary gland dysfunction results from p53-dependent apoptosis. Int J Radiat Oncol Biol Phys (2009) 1.34
Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin Cancer Res (2005) 1.32
Characterization of hARD2, a processed hARD1 gene duplicate, encoding a human protein N-alpha-acetyltransferase. BMC Biochem (2006) 1.30
New pertussis vaccination strategies beyond infancy: recommendations by the global pertussis initiative. Clin Infect Dis (2004) 1.29
Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res (2003) 1.27
Assessing the value of healthcare interventions using multi-criteria decision analysis: a review of the literature. Pharmacoeconomics (2014) 1.27
Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha. J Biol Chem (2006) 1.24
Constitutive/hypoxic degradation of HIF-alpha proteins by the proteasome is independent of von Hippel Lindau protein ubiquitylation and the transactivation activity of the protein. J Biol Chem (2007) 1.17
Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000. Clin Ther (2003) 1.11
Hypoxic regulation of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene family (PFKFB-1-4) expression in vivo. FEBS Lett (2003) 1.08
Collection and visualization of dietary behavior and reasons for eating using Twitter. J Med Internet Res (2013) 1.07
The promise of digital (mobile) health in cancer prevention and treatment. Future Oncol (2013) 1.07
Restoration of radiation therapy-induced salivary gland dysfunction in mice by post therapy IGF-1 administration. BMC Cancer (2010) 1.05
Functional conservation of erythropoietin signaling in zebrafish. Blood (2007) 1.05
Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. J Am Coll Cardiol (2005) 1.01
Can cost utility evaluations inform decision making about interventions for low back pain? Spine J (2009) 0.98
Malignant transformation of immortalized HaCaT keratinocytes through deregulated nuclear factor kappaB signaling. Cancer Res (2006) 0.98
Hypoxic regulation of PFKFB-3 and PFKFB-4 gene expression in gastric and pancreatic cancer cell lines and expression of PFKFB genes in gastric cancers. Acta Biochim Pol (2006) 0.95
Adenoviral E1A: everlasting tool, versatile applications, continuous contributions and new hypotheses. Front Biosci (2002) 0.95
(31) P and (1) H MRS of DB-1 melanoma xenografts: lonidamine selectively decreases tumor intracellular pH and energy status and sensitizes tumors to melphalan. NMR Biomed (2012) 0.95
Protocols for simulating the thermal component of fever: preclinical and clinical experience. Methods (2004) 0.94
Lonidamine induces intracellular tumor acidification and ATP depletion in breast, prostate and ovarian cancer xenografts and potentiates response to doxorubicin. NMR Biomed (2014) 0.94
Are proton pump inhibitors the first choice for acute treatment of gastric ulcers? A meta analysis of randomized clinical trials. BMC Gastroenterol (2002) 0.93
Health and economic consequences of an outbreak of pertussis among healthcare workers in a hospital in France. Infect Control Hosp Epidemiol (2005) 0.93
Sodium selenite increases the activity of the tumor suppressor protein, PTEN, in DU-145 prostate cancer cells. Nutr Cancer (2009) 0.91
Lifespan-extending caloric restriction or mTOR inhibition impair adaptive immunity of old mice by distinct mechanisms. Aging Cell (2014) 0.89
Prevention of radiation-induced salivary gland dysfunction utilizing a CDK inhibitor in a mouse model. PLoS One (2012) 0.87
Improving tumor response to radiotherapy by targeting angiogenesis signaling pathways. Hematol Oncol Clin North Am (2004) 0.87
Hormesis and synergy: pathways and mechanisms of quercetin in cancer prevention and management. Nutr Rev (2010) 0.87
Quercetin selectively inhibits bioreduction and enhances apoptosis in melanoma cells that overexpress tyrosinase. Nutr Cancer (2007) 0.87
Metaiodobenzylguanidine and hyperglycemia augment tumor response to isolated limb perfusion in a rodent model of human melanoma. Ann Surg Oncol (2004) 0.85
HHV-8-associated multicentric Castleman's disease in HIV-negative patient: a novel therapy for an orphan disease. Oncologist (2012) 0.85
Expression and hypoxia-responsiveness of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 in mammary gland malignant cell lines. Acta Biochim Pol (2005) 0.84
Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73. BMC Cancer (2010) 0.84
Effects of hyperthermia on p53 protein expression and activity. J Cell Physiol (2002) 0.83
Kadota Fund International Forum 2004. Application of thermal stress for the improvement of health, 15-18 June 2004, Awaji Yumebutai International Conference Center, Awaji Island, Hyogo, Japan. Final report. Int J Hyperthermia (2008) 0.82
Contrasting effects of chronic, systemic treatment with mTOR inhibitors rapamycin and metformin on adult neural progenitors in mice. Age (Dordr) (2013) 0.82
Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS. Am J Cardiovasc Drugs (2010) 0.81
Effects of hyperglycemia on lonidamine-induced acidification and de-energization of human melanoma xenografts and sensitization to melphalan. NMR Biomed (2015) 0.79
Combination of vandetanib, radiotherapy, and irinotecan in the LoVo human colorectal cancer xenograft model. Int J Radiat Oncol Biol Phys (2009) 0.79
Immunophilin-ligands FK506 and CsA inhibit HIF1alpha expression by a VHL- and ubiquitin-independent mechanism. FEBS Lett (2006) 0.79
The global pertussis initiative: Meeting report from the Regional Latin America Meeting, Costa Rica, 5-6 December, 2008. Hum Vaccin (2010) 0.78
Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of type 2 diabetes mellitus. Clin Ther (2002) 0.77
Pertussis in adolescents and adults: should we accept the results? Pediatrics (2005) 0.77
Tumor oxygenation and acidification are increased in melanoma xenografts after exposure to hyperglycemia and meta-iodo-benzylguanidine. Radiat Res (2003) 0.77
Tyrosinase overexpression promotes ATM-dependent p53 phosphorylation by quercetin and sensitizes melanoma cells to dacarbazine. Cell Oncol (2008) 0.77
Effect of simultaneous inhibition of epidermal growth factor receptor and cyclooxygenase-2 in HER-2/neu-positive breast cancer. Clin Cancer Res (2006) 0.77
Cyclooxygenase (COX)-2-dependent effects of the inhibitor SC236 when combined with ionizing radiation in mammary tumor cells derived from HER-2/neu mice. Mol Cancer Ther (2004) 0.77
Erythropoietin levels in patients with sickle cell disease do not correlate with known inducers of erythropoietin. Hemoglobin (2014) 0.76
Exploiting tyrosinase expression and activity in melanocytic tumors: quercetin and the central role of p53. Integr Cancer Ther (2010) 0.76
Factors controlling oxygen utilization. Adv Exp Med Biol (2005) 0.76
Thermal sensitisation by lonidamine of human melanoma cells grown at low extracellular pH. Int J Hyperthermia (2013) 0.76
[Cost-effectiveness analysis of using high doses of atorvastatin for the secondary stroke prevention in Spain]. Rev Neurol (2010) 0.75
Effect of mild hyperglycemia +/- meta-iodo-benzylguanidine on the radiation response of R3230 Ac tumors. Adv Exp Med Biol (2003) 0.75
[Discrete-event simulation models in the economic evaluation of health technologies and health products]. Gac Sanit (2008) 0.75
³¹P-MRS studies of melanoma xenografts with different metastatic potential. Adv Exp Med Biol (2011) 0.75
Enhanced response to basiliximab in a patient with aplastic anemia after treatment with standard immunosuppression. Am J Hematol (2002) 0.75